Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320350 | 0.90 | GPR119 (0.42) | GRM5GPR119GPR183SCD5USP30 | |
| SCHEMBL15673719 | 0.89 | GPR119 (0.45) | GRM5GPR119GPR183CYP3A4SCD5 | |
| SCHEMBL15673214 | 0.89 | SCD5 (0.44) | GPR119GPR183SCD5JAK2JAK1 | |
| SCHEMBL136771 | 0.88 | GRM5 (0.53) | GRM5CYP3A4 | |
| SCHEMBL133024 | 0.85 | GRM5 (0.41) | GRM5CYP3A4 | |
| SCHEMBL136509 | 0.84 | GRM5 (0.49) | GRM5CYP3A4 | |
| SCHEMBL136382 | 0.83 | GPR119 (0.46) | GPR119SCD5JAK2JAK1 | |
| SCHEMBL136209 | 0.83 | GRM5 (0.56) | GRM5CYP3A4 | |
| SCHEMBL135952 | 0.83 | GRM5 (0.49) | GRM5CYP3A4 | |
| SCHEMBL139777 | 0.83 | GRM5 (0.44) | GRM5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580962-B2 | Spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD. (IT) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GPR65, GRIK5 | GRM5 1/4885GPR119 142/4885STS 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.